Sal, it would 'appear' that the requisite conditions leading up to a NASDAQ uplisting have been met. What I believe unduly added to a significant downturn was the unplanned 1-month waiting pewriod between Quorums, wherein the 1st Quorum on August 3rd was not met due to a lack of votes, and subsequently required a 2nd one on Sept., 2nd. This caused alot of doubt as to whether they actually had enough votes to fulfill the 2nd Quorum. Some speculated going back out to the 2nd series of shareholders included those shareholders who bought more recently, as opposed to theose who sold. Regradless, the share price dropped from the $4's to low $2's, and has only continued it's 'nose bleed' decline since.
But you are correct. Multiple Ph. 2 candidates, CLIA for LymPro and MS Precise, as well as ESS test trials and Eltopa results, all in 4Q15, along with an NASDAQ up listing, will make this a double digit stock rather quickly.
My concern at present is with AMBS's balance sheet and declining shareprice. These have only contributed to up listing from weakness. I suspect the NASDAQ is reviewing these issues as well. If they obtain significant non-dilutive funding, or strike a sizeable JV Partnership prior to up listing, I believe it will "grease the skids" so to speak for NASDAQ to make their final ruling in favor of AMBS.
Contrarily, if AMBS recieves the nod from the NASDAQ before obtaining significant non-dilutive financing, or striking a sizeable JV Partnership, then its well accepted that AMBS has institutional investors willing to take positions in a new NASDAQ kid on the block. Couple that with a successful Dx spin off, shelf offering and capital raise, things could get interesting quickly - something we all hope for, with some praying hard along the way....
News 
Market Data 
Discover 
